0

Digital Health Care is already fully utilized in the US, isn’t it?

Dr. Stefan Walzer and Kate Claessens, the experienced consultant on healthcare in the US, are discussing the public acceptance as well as the various reimbursement pathways in the USA. What is the status of digital health care in the USA? How does reimbursement work for the different paths? What changes might… Continue Reading

0

Does the Italian reimbursement pathway allow for innovative drugs being highly priced, Dr. Stefano Capri and Dr. Entela Xoxi?

The Italian reimbursement system is unique in terms of its structure, especially also for innovative drugs. However, what does the new innovation pathway means to the industry and health care availability? How easy is it really to negotiate a premium price? Listen to the discussions and explanations of Dr Stefan Walzer and… Continue Reading

0

The private health insurances as the entrance into German market access – is this true, Dr. Bastian Biermann?

The German health care system consists of the statutory and private health insurances, whereas the latter covers around 10% of the population. Anyhow, access and commercialization, especially of new and innovative therapies could firstly be introduced through the private system.… Continue Reading